Skip to main content
BioCentury on BioBusiness
Feature Story

Cover Story: Product Development: Prevention by the pound

Why Janssen created stand-alone group to stop diseases from starting

By Susan Schaeffer, Editor

Both the greatest promise and the biggest challenge in treating progressive diseases lie in intervening early, before disease processes become too complex to intercept and damage to tissues and systems becomes irreversible. In many settings, basic and translational research are beginning to reveal the molecular drivers of the transition from healthy to disease states, offering the tantalizing prospect of cutting these processes off before illness even begins.

There have been numerous successful examples of intercepting disease with pharmaceuticals in cardiovascular disease, and several companies have an interception program here or there in other disease areas. But for the most part the pharmaceutical R&D apparatus isn't set up for large scale, rapid development of interventions that can interrupt the transition from health to disease. Nor is the regulatory system set up to run trials in this setting in a meaningful time frame and at a reasonable cost.

Read Article
  • THE DISTILLERY brings you this week's most essential scientific findings in therapeutics, distilled by Innovations editors from a weekly review of more than 400 papers in 41 of the highest-impact journals in the fields of biotechnology, the life sciences and chemistry. The Distillery goes beyond the abstracts to explain the commercial relevance of featured research, including licensing status and companies working in the field, where applicable.

    This week in therapeutics includes important research findings on targets and compounds, grouped first by disease class and then alphabetically by indication.

    This week in techniques includes findings about research tools, disease models and manufacturing processes that have the potential to enable or improve all stages of drug discovery and development.

Subscribe Now
Free Trial